参考文献：

［1］中国侵袭性真菌感染工作组.血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则（第五次修订版）［J］.中华内科杂志，2017，56（6）：453-459.

［2］SCHMIEDEL,YVONNE,STEPHAN ZIMMERLI.Common invasive fungal diseases: an overview of invasive candidiasis,aspergillosis,cryptococcosis,and Pneumocystis pneumonia［J］.Swiss Medical Weekly ,2016,146:14281.

［3］王宇，胡瑾华.肝衰竭合并真菌感染发病特点及预后影响因素［J］.临床肝胆病杂志，2019（2）：419-423.

［4］陆晖，李孟英，谭可平，等.不同真菌感染对肝衰竭患者病情及预后影响的研究［J］.肝脏，2017（4）：332-334.

［5］杨中原，陈韬.终末期肝病合并侵袭性真菌感染的治疗［J］.传染病信息，2019（3）：199-202.

［6］姜华，李春梅，南岩东，等.侵袭性肺毛霉菌病诊治及预后分析［J］.中华肺部疾病杂志（电子版），2018（6）：659-663.

［7］KENNEDY,K J,et al. Mucormycosis in Australia:contemporary epidemiology and outcomes［J］. Clinical Microbiology and Infection:the OfficialPublication of the European Society of Clinical Microbiology and Infectious Disease,2016,22:775-781.(https://www.daowen.com)

［8］LANTERNIER,F,et al. A global analysis of mucormycosis in France: the RetroZygo Study（2005～2007）［J］. Clinical Infectious Diseases:an Official Publication of the Infectious Diseases Society of America,2012,54:S35-43.

［9］SPELLBERG,BRAD,et al.Risk factors for mortality in patients with mucormycosis［J］.Medical Mycology,2012,50（6）:611-618.

［10］ZILBERBERG,MARYA D,et al. Hospital days,hospitalization costs,and inpatient mortality among patients with mucormycosis:a retrospective analysis of US hospital discharge data ［J］.BMC Infectious Diseases,2014,14:310.

［11］HAMILOS,GEORGIOS,et al.Pulmonary mucormycosis.Seminars in Respiratory and Critical Care Medicine,2011,32:693-702.

［12］VERCILLO,MICHAEL S,et al.Early pneumonectomy for pulmonary mucormycosis［J］.The Annals of Thoracic Surgery,2015,99:61.

（王香梅　高海兵　林明华）